Skip to content

AVEO (NASDAQ: AVEO), founded in 2003, is a publicly traded biopharmaceutical company dedicated to advancing a broad portfolio of targeted medicines for oncology and other areas of unmet medical need. The company’s strategy is to retain North American rights to its oncology portfolio while securing partners in development and commercialization outside of North America.

Latest News from Aveo Oncology